{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:22:12Z","timestamp":1791638532344,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA 000389"],"award-info":[{"award-number":["Z1A DA 000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA 000389"],"award-info":[{"award-number":["Z1A DA 000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000424"],"award-info":[{"award-number":["Z1A DA000424"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA000389"],"award-info":[{"award-number":["Z1A DA000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["Z1A DA 000389"],"award-info":[{"award-number":["Z1A DA 000389"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA032701"],"award-info":[{"award-number":["R01 DA032701"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA032701"],"award-info":[{"award-number":["R01 DA032701"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DA032701"],"award-info":[{"award-number":["R01 DA032701"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1038\/s41386-019-0366-z","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T09:03:08Z","timestamp":1552294988000},"page":"1435-1444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-9474","authenticated-orcid":false,"given":"Amy Hauck","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline D.","family":"Keighron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-227X","authenticated-orcid":false,"given":"Chloe J.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-4743","authenticated-orcid":false,"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara M.","family":"Abramyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia J.","family":"Avelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Tschumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Beckstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-9878","authenticated-orcid":false,"given":"Gianluigi","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8104","authenticated-orcid":false,"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11904-018-0398-8","volume":"15","author":"K Johnson","year":"2018","unstructured":"Johnson K, Jones C, Compton W, Baldwin G, Fan J, Mermin J, et al. Federal response to the opioid crisis. Curr HIV\/AIDS Rep. 2018;15:293\u2013301.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377:391\u20134.","journal-title":"N Engl J Med"},{"key":"366_CR3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMc1809521","volume":"379","author":"UG Khatri","year":"2018","unstructured":"Khatri UG, Viner K, Perrone J. Lethal fentanyl and cocaine intoxication. N Engl J Med. 2018;379:1782.","journal-title":"N Engl J Med"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/pr.115.011668","volume":"68","author":"PW Czoty","year":"2016","unstructured":"Czoty PW, Stoops WW, Rush CR. Evaluation of the \u201cPipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68:533\u201362.","journal-title":"Pharmacol Rev"},{"key":"366_CR5","first-page":"305","volume":"10","author":"J Ballester","year":"2017","unstructured":"Ballester J, Valentine G, Sofuoglu M. Pharmacological treatments for methamphetamine addiction: current status and future directions. Expert Rev Clin Pharmacol. 2017;10:305\u201314.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"366_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugalcdep.2015.08.005","volume":"155","author":"KM Kampman","year":"2015","unstructured":"Kampman KM, Lynch KG, Pettinati HM, Spratt K, Wierzbicki MR, Dackis C, et al. A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend. 2015;155:105\u201310.","journal-title":"Drug Alcohol Depend"},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","volume":"120","author":"AL Anderson","year":"2012","unstructured":"Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120:135\u201341.","journal-title":"Drug Alcohol Depend"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","volume":"229","author":"M Mereu","year":"2013","unstructured":"Mereu M, Bonci A, Newman AH, Tanda G. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology. 2013;229:415\u201334.","journal-title":"Psychopharmacology"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","volume":"72","author":"CJ Loland","year":"2012","unstructured":"Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, et al. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012;72:405\u201313.","journal-title":"Biol Psychiatry"},{"key":"366_CR10","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.1021\/acs.jmedchem.6b01373","volume":"59","author":"J Cao","year":"2016","unstructured":"Cao J, Slack RD, Bakare OM, Burzynski C, Rais R, Slusher BS, et al. Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors. J Med Chem. 2016;59:10676\u201391.","journal-title":"J Med Chem"},{"key":"366_CR11","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/jm401754x","volume":"57","author":"OM Okunola-Bakare","year":"2014","unstructured":"Okunola-Bakare OM, Cao J, Kopajtic T, Katz JL, Loland CJ, Shi L, et al. Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues. J Med Chem. 2014;57:1000\u201313.","journal-title":"J Med Chem"},{"key":"366_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1021\/ml1002025","volume":"2","author":"J Cao","year":"2010","unstructured":"Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, Katz JL, et al. Structure-activity relationships at the monoamine transporters for a novel series of modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) analogues. ACS Med Chem Lett. 2010;2:48\u201352.","journal-title":"ACS Med Chem Lett"},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1054-3589(08)57007-4","volume":"57","author":"G Tanda","year":"2009","unstructured":"Tanda G, Newman AH, Katz JL. Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol. 2009b;57:253\u201389.","journal-title":"Adv Pharmacol"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/mol.107.039800","volume":"73","author":"CJ Loland","year":"2008","unstructured":"Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, et al. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol. 2008;73:813\u201323.","journal-title":"Mol Pharmacol"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.12.006","volume":"131","author":"BJ Tunstall","year":"2018","unstructured":"Tunstall BJ, Ho CP, Cao J, Vendruscolo JCM, Schmeichel BE, Slack RD, et al. Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats. Neuropharmacology. 2018;131:96\u2013103.","journal-title":"Neuropharmacology"},{"key":"366_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22087-1","volume":"8","author":"X Li","year":"2018","unstructured":"Li X, Peng XQ, Jordan CJ, Li J, Bi GH, He Y, et al. mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. Sci Rep. 2018;8:3686.","journal-title":"Sci Rep"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1021\/jm501512b","volume":"58","author":"TM Keck","year":"2015","unstructured":"Keck TM, John WS, Czoty PW, Nader MA, Newman AH. Identifying medication targets for psychostimulant addiction: unraveling the dopamine D3 receptor hypothesis. J Med Chem. 2015;58:5361\u201380.","journal-title":"J Med Chem"},{"key":"366_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/npp.2016.155","volume":"42","author":"ZX Xi","year":"2017","unstructured":"Xi ZX, Song R, Li X, Lu GY, Peng XQ, He Y, et al. CTDP-32476: a promising agonist therapy for treatment of cocaine addiction. Neuropsychopharmacology. 2017;42:682\u201394.","journal-title":"Neuropsychopharmacology"},{"key":"366_CR19","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/sj.npp.1300912","volume":"31","author":"ZX Xi","year":"2006","unstructured":"Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr., et al. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine\u2019s rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology. 2006;31:1393\u2013405.","journal-title":"Neuropsychopharmacology"},{"key":"366_CR20","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/npp.2017.41","volume":"42","author":"HY Zhang","year":"2017","unstructured":"Zhang HY, Bi GH, Yang HJ, He Y, Xue G, Cao J, et al. The novel modafinil analog, JJC8-016, as a potential cocaine abuse pharmacotherapeutic. Neuropsychopharmacology. 2017;42:1871\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"366_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.biopsych.2010.07.026","volume":"69","author":"L Garces-Ramirez","year":"2011","unstructured":"Garces-Ramirez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas AM, et al. Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry. 2011;69:208\u201317.","journal-title":"Biol Psychiatry"},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.biopsych.2014.03.031","volume":"76","author":"SJ Kohut","year":"2014","unstructured":"Kohut SJ, Hiranita T, Hong SK, Ebbs AL, Tronci V, Green J, et al. Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine. Biol Psychiatry. 2014;76:802\u20139.","journal-title":"Biol Psychiatry"},{"key":"366_CR23","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1126\/science.276.5321.2048","volume":"276","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997a;276:2048\u201350.","journal-title":"Science"},{"key":"366_CR24","doi-asserted-by":"publisher","unstructured":"Keighron JD, Giancola JB, Shaffer RJ, DeMarco EM, Coggiano MA, Slack RD, et al. (2018). Distinct effects of (R)-modafinil and its (R)- and (S)-fluoro-analogs on mesolimbic extracellular dopamine assessed by voltammetry and microdialysis in rats. Eur J Neurosci. \n                    https:\/\/doi.org\/10.1111\/ejn.14256","DOI":"10.1111\/ejn.14256"},{"key":"366_CR25","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1471-4159.2011.07407.x","volume":"119","author":"ES Ramsson","year":"2011","unstructured":"Ramsson ES, Howard CD, Covey DP, Garris PA. High doses of amphetamine augment, rather than disrupt, exocytotic dopamine release in the dorsal and ventral striatum of the anesthetized rat. J Neurochem. 2011;119:1162\u201372.","journal-title":"J Neurochem"},{"key":"366_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuropharm.2017.06.016","volume":"123","author":"AJ Avelar","year":"2017","unstructured":"Avelar AJ, Cao J, Newman AH, Beckstead MJ. Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons. Neuropharmacology. 2017;123:410\u20139.","journal-title":"Neuropharmacology"},{"key":"366_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.neuropharm.2013.10.010","volume":"77","author":"R Song","year":"2014","unstructured":"Song R, Bi GH, Zhang HY, Yang RF, Gardner EL, Li J, et al. Blockade of D3 receptors by YQA14 inhibits cocaine\u2019s rewarding effects and relapse to drug-seeking behavior in rats. Neuropharmacology. 2014;77:398\u2013405.","journal-title":"Neuropharmacology"},{"key":"366_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","volume":"66","author":"NR Richardson","year":"1996","unstructured":"Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods. 1996;66:1\u201311.","journal-title":"J Neurosci Methods"},{"key":"366_CR29","unstructured":"Van Der Zee P, Koger HS, Gootjes J, Hespe W. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem.1980;15:363\u201370."},{"key":"366_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12399-z","volume":"7","author":"X Han","year":"2017","unstructured":"Han X, He Y, Bi GH, Zhang HY, Song R, Liu QR, et al. CB1 receptor activation on VgluT2-expressing glutamatergic neurons underlies delta(9)-tetrahydrocannabinol (delta(9)-thc)-induced aversive effects in mice. Sci Rep. 2017;7:12315.","journal-title":"Sci Rep"},{"key":"366_CR31","doi-asserted-by":"publisher","first-page":"12304","DOI":"10.1073\/pnas.92.26.12304","volume":"92","author":"FE Pontieri","year":"1995","unstructured":"Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the \u201cshell\u201d as compared with the \u201ccore\u201d of the rat nucleus accumbens. Proc Natl Acad Sci USA. 1995;92:12304\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"366_CR32","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/j.1460-9568.1997.tb01375.x","volume":"9","author":"G Tanda","year":"1997","unstructured":"Tanda G, Pontieri FE, Frau R, Di Chiara G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci. 1997b;9:2077\u201385.","journal-title":"Eur J Neurosci"},{"key":"366_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1113\/jphysiol.1996.sp021805","volume":"497","author":"M Miele","year":"1996","unstructured":"Miele M, Boutelle MG, Fillenz M. The source of physiologically stimulated glutamate efflux from the striatum of conscious rats. J Physiol. 1996;497:745\u201351.","journal-title":"J Physiol"},{"key":"366_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0304-3940(00)00813-2","volume":"281","author":"EA Budygin","year":"2000","unstructured":"Budygin EA, Kilpatrick MR, Gainetdinov RR, Wightman RM. Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry. Neurosci Lett. 2000;281:9\u201312.","journal-title":"Neurosci Lett"},{"key":"366_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.neuron.2004.05.019","volume":"42","author":"MJ Beckstead","year":"2004","unstructured":"Beckstead MJ, Grandy DK, Wickman K, Williams JT. Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron. 2004;42:939\u201346.","journal-title":"Neuron"},{"key":"366_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1152\/jn.00094.2012","volume":"108","author":"SY Branch","year":"2012","unstructured":"Branch SY, Beckstead MJ. Methamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currents. J Neurophysiol. 2012;108:802\u20139.","journal-title":"J Neurophysiol"},{"key":"366_CR37","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1021\/acs.jmedchem.7b01454","volume":"60","author":"MF Zou","year":"2017","unstructured":"Zou MF, Cao J, Abramyan AM, Kopajtic T, Zanettini C, Guthrie DA, et al. Structure-Activity relationship studies on a series of 3alpha-[Bis(4-fluorophenyl)methoxy]tropanes and 3alpha-[Bis(4-fluorophenyl)methylamino]tropanes as novel atypical dopamine transporter (DAT) inhibitors for the treatment of cocaine use disorders. J Med Chem. 2017;60:10172\u201387.","journal-title":"J Med Chem"},{"key":"366_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neuropharm.2010.08.021","volume":"60","author":"H Bisgaard","year":"2011","unstructured":"Bisgaard H, Larsen MA, Mazier S, Beuming T, Newman AH, Weinstein H, et al. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology. 2011;60:182\u201390.","journal-title":"Neuropharmacology"},{"key":"366_CR39","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1021\/acschemneuro.7b00094","volume":"8","author":"AM Abramyan","year":"2017","unstructured":"Abramyan AM, Stolzenberg S, Li Z, Loland CJ, Noe F, Shi L. The isomeric preference of an atypical dopamine transporter inhibitor contributes to its selection of the transporter conformation. ACS Chem Neurosci. 2017;8:1735\u201346.","journal-title":"ACS Chem Neurosci"},{"key":"366_CR40","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1021\/acs.jpcb.7b10340","volume":"122","author":"MH Cheng","year":"2018","unstructured":"Cheng MH, Kaya C, Bahar I. Quantitative assessment of the energetics of dopamine translocation by human dopamine transporter. J Phys Chem B. 2018;122:5336\u201346.","journal-title":"J Phys Chem B"},{"key":"366_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep40076","volume":"7","author":"AM Razavi","year":"2017","unstructured":"Razavi AM, Khelashvili G, Weinstein H. A Markov state-based quantitative kinetic model of sodium release from the dopamine transporter. Sci Rep. 2017;7:40076.","journal-title":"Sci Rep"},{"key":"366_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1124\/jpet.108.145813","volume":"329","author":"T Hiranita","year":"2009","unstructured":"Hiranita T, Soto PL, Newman AH, Katz JL. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther. 2009;329:677\u201386.","journal-title":"J Pharmacol Exp Ther"},{"key":"366_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ejn.13376","volume":"45","author":"M Mereu","year":"2017","unstructured":"Mereu M, Chun LE, Prisinzano TE, Newman AH, Katz JL, Tanda G. The unique psychostimulant profile of (+\/\u2212)-modafinil: investigation of behavioral and neurochemical effects in mice. Eur J Neurosci. 2017;45:167\u201374.","journal-title":"Eur J Neurosci"},{"key":"366_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.12.005","volume":"147","author":"ME Reith","year":"2015","unstructured":"Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, et al. Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend. 2015;147:1\u201319.","journal-title":"Drug Alcohol Depend"},{"key":"366_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00213-013-3109-6","volume":"229","author":"G Tanda","year":"2013","unstructured":"Tanda G, Li SM, Mereu M, Thomas AM, Ebbs AL, Chun LE, et al. Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change. Psychopharmacology. 2013;229:307\u201321.","journal-title":"Psychopharmacology"},{"key":"366_CR46","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1124\/jpet.109.154302","volume":"330","author":"G Tanda","year":"2009","unstructured":"Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, Tallarida RJ, et al. Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther. 2009a;330:802\u20139.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0366-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:47Z","timestamp":1684616747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-019-0366-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1038\/s41386-019-0366-z","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"21 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}